Lords Mark Industries Limited announced a strategic restructuring plan involving the demerger of its renewable energy and LED division into a separate entity, Lords Shakti Power Limited. The move aims to allow the energy business to pursue its capital programme independently while enabling the remaining healthcare and diagnostics businesses to be valued on their own fundamentals.

The Board of Directors proposed that Lords Mark Industries will hold a 60% stake in the new entity, with existing shareholders receiving shares in proportion to their current holdings. The scheme is expected to be filed by March 2027. Lords Shakti Power Limited will also enter the power transmission business through transformer manufacturing.

Financial Guidance for FY27

The company issued financial guidance for FY27, projecting significant growth driven primarily by its base businesses of in vitro diagnostics (IVD) and renewable energy & LED. Management expects consolidated revenue of at least ₹1,550 crore, representing growth of over 20% compared to FY26. Profit after tax (PAT) is guided at a minimum of ₹178 crore, reflecting growth of over 50% and a margin inflection of at least 200 basis points.

Management indicated that material contribution from the sickle cell testing business and the medical devices segment—comprising Onco Spectra and TB Truth—is expected from FY28 onward, as these units commence meaningful commercialisation.

Strategic Expansions and Partnerships

Lords Mark outlined several strategic initiatives across healthcare delivery and diagnostics:

• CAR-T Cell Therapy: The company plans an exclusive India agreement with a leading global manufacturer to establish laboratory and treatment capabilities across five centres. The first two centres in Mumbai and Bangalore are targeted to commence by March 2027, offering treatment at a substantially lower price point than currently available.
• International Subsidiaries: Lords Mark Industries UK Limited has been incorporated as the first Indian company to register in the UK following the India-UK Free Trade Agreement. It aims to be operational from January 2027, running a pathology laboratory supplied by the company’s Indian manufacturing base. A similar subsidiary is being established in Switzerland to extend regulated-market presence into continental Europe.
• Oncology Hospitals: Through subsidiary Lords Mark Medicine Limited, the company plans to launch owned oncology hospitals in tier-2 cities. Two pilot hospitals of approximately 70 beds each in Vapi and Solapur are targeted to open by March 2027, funded through a debt raise of approximately ₹200 crore in December 2026.
• Dialysis Network: The company proposes to establish 50 dialysis centres across India by March 2027. Operating from rented premises and equipped with its own RENALOS dialysis machines, this model shifts the business from equipment sales toward recurring, session-based service revenue.

Regulatory Approvals and Product Launches

Lords Mark reported regulatory milestones for its diagnostic platforms:

• OneDNA Genomic Testing: Patient trials for the OneDNA genomic testing platform have been completed, and approval has been received from the Indian Council of Medical Research (ICMR). An application to the Central Drugs Standard Control Organisation (CDSCO) is currently under process.
• Biomescan Analytics Platform: The company received a manufacturing licence for its Biomescan Analytics Platform, becoming the first and only company in India to receive such a licence for In Vitro Diagnostic Software (Software as a Medical Device – SaMD) under the Medical Devices Rules, 2017.

What the Numbers Show

The guidance indicates a divergence between top-line and bottom-line growth trajectories for FY27. While revenue is projected to grow over 20%, PAT is expected to grow over 50%. This acceleration in profitability, alongside a margin expansion of at least 200 basis points to 11.4%, suggests that the company anticipates operating leverage or improved cost structures in its core IVD and renewable energy segments, rather than pure volume-driven growth alone.

Lord's Mark Industries Limited reported a standalone net profit of ₹32.16 crore for the quarter ended June 30, 2026, marking a significant turnaround from the ₹0.03 crore loss recorded in Q1FY25. The company’s consolidated net profit for the period was ₹33.18 crore, up from a ₹0.03 crore loss in the corresponding quarter of the previous year.

Standalone revenue from operations declined 36.6% quarter-on-quarter (QoQ) to ₹280.36 crore, down from ₹441.98 crore in Q4FY25. Consolidated revenue from operations also contracted 37.3% QoQ to ₹307.68 crore, compared to ₹491.17 crore in the prior quarter.

Financial Performance

The Board of Directors approved the unaudited financial results at its meeting held on August 13, 2026. The results were reviewed by the Audit Committee and limited reviewed by statutory auditors Sanjeev S Gupta & Associates.

What the Numbers Show

Despite the decline in top-line revenue, Lord's Mark Industries improved its profitability margins significantly compared to the previous year. While standalone revenue fell 36.6% QoQ, the company managed to reduce total expenses by 37.6% QoQ to ₹241.30 crore. This cost discipline allowed the firm to post a profit before tax of ₹43.92 crore, contrasting sharply with the ₹0.03 crore loss in Q1FY25.

Balance Sheet and Cash Flow

As of June 30, 2026, the standalone balance sheet showed total assets of ₹1,380.16 crore, an increase from ₹1,305.88 crore at the end of FY25. Current assets rose to ₹959.37 crore, driven largely by short-term loans and advances which jumped to ₹307.96 crore from ₹66.97 crore in March 2026. Trade receivables declined to ₹394.75 crore from ₹562.00 crore.

Consolidated total assets stood at ₹1,491.55 crore, up from ₹1,443.02 crore. Long-term borrowings decreased slightly to ₹138.88 crore from ₹145.84 crore, while short-term borrowings fell to ₹218.91 crore from ₹238.34 crore.

Corporate Developments

The financial statements reflect the amalgamation of Lord's Mark Industries Limited with Kratos Energy & Infrastructure Limited, pursuant to an order passed by the NCLT Mumbai. The resultant entity continues to operate under the name Lord's Mark Industries Limited. The consolidated accounts include four subsidiaries: Lords Mark Tech Next Private Limited, Lords Green Energy Private Limited, Renalyx Health Systems Private Limited, and Lords Mark Micro Biotech Private Limited.